News

What to Expect from Tractor Supply's Upcoming Earnings Report

What to Expect from Tractor Supply's Upcoming Earnings Report

What to Expect from Tractor Supply's Upcoming Earnings Report

Tractor Supply (NASDAQ: TSCO) is getting ready to announce its quarterly earnings, and investors are eager to know what this could mean for the company's future. With expectations high, it's crucial to look at the elements that may impact this announcement.

Analysts predict that Tractor Supply will report an earnings per share (EPS) of $2.23. This figure not only sets a benchmark for the company's performance but also serves as an indicator for investor sentiment.

Investors are particularly interested in the guidance that Tractor Supply will provide for the upcoming quarter. Positive guidance can significantly boost stock prices, making it a critical component of the earnings report.

Examining Historical Earnings

Looking back at the most recent earnings release, Tractor Supply missed its EPS target by $0.00 yet still experienced a minor increase in share price, rising by 1.97% in the following trading session. Understanding how the company has performed in the past can offer insights into expectations for the current quarter.

Reviewing Tractor Supply's previous earnings shows a mix of performance:

Here are some highlights from previous quarters:

Quarterly Performance

  • Q2 2024: EPS Estimate: 3.93, EPS Actual: 3.93, Price Change: 2.0%
  • Q1 2024: EPS Estimate: 1.72, EPS Actual: 1.83, Price Change: 3.0%
  • Q4 2023: EPS Estimate: 2.22, EPS Actual: 2.28, Price Change: -1.0%
  • Q3 2023: EPS Estimate: 2.29, EPS Actual: 2.33, Price Change: -1.0%

Tracking Stock Performance

As of recent trading days, shares of Tractor Supply were noted at $291.44. Over the past year, the stock has shown a robust increase of approximately 54.08%. Such strong performance typically fosters a bullish sentiment among long-term shareholders leading into quarterly earnings.

Analytic Insights on Tractor Supply

For informed investment decisions, understanding market sentiments and expectations is vital. Recent analyses covering Tractor Supply reflect a distinct consensus:

With 16 analyst ratings, the general sentiment is a Buy, reinforcing confidence in the company's trajectory. The one-year price target averages around $298.12, indicating a possible upside of about 2.29%.

Peer Comparisons: A Broader Perspective

It's valuable to examine how Tractor Supply performs relative to significant players in the industry, including Ulta Beauty, Dick's Sporting Goods, and Chewy. Such comparisons provide additional context regarding expectations and market positions.

  • Ulta Beauty showcases a Neutral trajectory with a price target of $415.62, suggesting an impressive 42.61% upside.
  • Dick's Sporting Goods maintains a Neutral trajectory with a price target of $243.19, indicating a potential decline of 16.56%.
  • Chewy carries an Outperform rating with a price target of $31.43, reflecting a notable potential downside of 89.22%.

Peer Analysis Summary

The peer analysis of companies highlights key financial metrics:

  • Tractor Supply: Consensus - Buy, Revenue Growth - 1.48%, Gross Profit - $1.56B, Return on Equity - 19.20%
  • Ulta Beauty: Consensus - Neutral, Revenue Growth - 0.88%, Gross Profit - $978.18M, Return on Equity - 10.87%
  • Dick's Sporting Goods: Consensus - Neutral, Revenue Growth - 7.75%, Gross Profit - $1.28B, Return on Equity - 12.91%
  • Chewy: Consensus - Outperform, Revenue Growth - 2.63%, Gross Profit - $843.84M, Return on Equity - 52.96%

The takeaway from these comparisons indicates that Tractor Supply excels in Gross Profit and Return on Equity within its peer group, thus showcasing resilience amid varying market conditions.

Understanding Tractor Supply's Operations

As a major retail operator for farms and ranches across the United States, Tractor Supply caters to recreational farmers and ranchers, steering clear of extensive exposure to commercial farming. Operating more than 2,200 locations nationwide, their stores are strategically placed in rural areas, contributing to a focused customer base.

Fiscal data reveals that revenue is primarily sourced from livestock and agriculture sales (27%), companion animals (25%), and seasonal needs (22%). This diverse revenue stream underlines the company's vast market coverage.

Financial Performance Breakdown

Market Capitalization: Tractor Supply boasts a market capitalization that eclipses many peers, underscoring its prominent place in the marketplace.

Revenue Growth: The recent revenue growth rate of 1.48% highlights a successful uptrend, allowing the company to stand out not just against competitors but within the broader Consumer Discretionary sector.

Net Margin: The company's net margin stands at an impressive 10.01%, indicating effective cost management and profitability, well above industry standards.

Return on Equity (ROE): With an ROE of 19.2%, Tractor Supply effectively utilizes its equity capital, showcasing its potential to generate returns for shareholders.

Return on Assets (ROA): The performance in terms of ROA is also strong, reaching 4.4%, further illustrating solid asset management and financial health.

Debt Management: The careful approach to debt management sees a debt-to-equity ratio below industry averages at 2.22, keeping financial risks at bay.

Frequently Asked Questions

What is the expected EPS for Tractor Supply's earnings report?

The expected earnings per share (EPS) for Tractor Supply's earnings report is $2.23.

How have Tractor Supply's shares performed over the past year?

Over the last 52 weeks, Tractor Supply's shares have increased approximately 54.08%.

What is the consensus rating for Tractor Supply among analysts?

The consensus rating among analysts for Tractor Supply is a Buy.

What kind of revenue does Tractor Supply generate?

Tractor Supply generates revenue primarily from livestock and agriculture, companion animals, and seasonal and recreational needs.

How does Tractor Supply compare with its peers in the market?

Tractor Supply excels in Gross Profit and Return on Equity compared to its peers and maintains a solid financial performance overall.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading